Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Solomon Moshkevich, President, Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), sold a total of 1,940 shares of common stock in two separate transactions. The sales, which totaled $299,179, were executed at prices ranging from $139.29 to $156.8505. The transactions occurred as Natera, currently valued at $19.2 billion, approaches its next earnings release on July 31. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with notable price volatility in recent months.
On May 27, 2025, Moshkevich sold 1,649 shares at a price of $156.8505 per share. Following this transaction, Moshkevich directly owns 128,556 shares of Natera, Inc.
A subsequent sale occurred on July 21, 2025, with Moshkevich selling 291 shares at $139.29 per share. Following this transaction, Moshkevich directly owns 128,265 shares of Natera, Inc.
The sales were effected to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and were made pursuant to a pre-arranged trading plan under Rule 10b5-1(c).
In other recent news, Natera reported its first-quarter 2025 earnings, exceeding analysts’ expectations with an earnings per share of -$0.50, compared to the projected -$0.64. The company’s revenue reached $522 million, reflecting a 37% increase year-over-year. In addition, Medicare has expanded coverage for Natera’s Signatera MRD assay to include a broader range of cancers, following a significant pan-cancer study presented at the American Society of Clinical Oncology Annual Meeting. RBC Capital Markets maintained an Outperform rating on Natera, with a price target of $251, attributing the company’s strong performance to effective commercial execution and the expansion of Medicare Advantage. TD Cowen also expressed a positive outlook, raising the price target to $200 due to Natera’s impressive sales performance, which was 13% higher than anticipated. Furthermore, Natera’s Signatera product saw a substantial increase in clinical volumes, rising to approximately 17,000 in the first quarter, marking a 52% year-over-year growth. Leerink Partners reiterated its Outperform rating with a price target of $220, citing recent Medicare coverage developments for Natera’s WGS Signatera assay. These developments highlight Natera’s ongoing momentum in the market and its expanding reach in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.